OTC:MWAI
MedWellAI, Inc.
An AI-powered healthcare technology firm offering digital diagnostics and workflow automation solutions to optimize clinical operations.
Key Metrics
Investment Thesis
Bull Case
Investors may view MWAI as a high-risk turnaround play if the AI healthcare sector rebounds and the company secures new major contracts to reverse its revenue decline. The low capital expenditure structure of $2,242 suggests an asset-light model that could become profitable once operating leverage is achieved again. Potential for strategic acquisition by larger health-tech firms could provide an exit route given the company's intellectual property in AI diagnostics.
Bear Case
The severe contraction in revenue and continued deep losses make the stock a poor investment with limited upside potential in the current economic environment. The negative shareholders' equity of -$2.3M and a massive deficit in retained earnings indicate the company is burning through capital without a clear path to profitability. OTC trading status combined with financial distress limits liquidity and increases the risk of delisting or bankruptcy.
About MedWellAI, Inc.
MedWellAI (MWAI) is an artificial intelligence-driven healthcare technology provider operating on the OTC market, focusing on digital health solutions that leverage machine learning for medical data analysis. The company serves a global market with proprietary software designed to streamline clinical workflows and enhance diagnostic accuracy. Key products include predictive analytics platforms integrated into electronic health records for hospitals and specialty clinics.
Analysis
Management Discussion
Despite a nominal gross profit of $594k, the company reported an operating loss of $2.8M and a net loss of $3.8M in 2025, indicating that revenue growth failed to cover escalating general and administrative costs. The drastic drop in revenue from $5.9M in 2024 to $0.6M in 2025 correlates with a sharp decline in net income from -$11.5M to -$3.8M, signaling severe operational instability. Cash flow from operations turned negative at -$848k while the company ended the period with $401k in cash, depleting reserves rapidly.
Industry Overview
The artificial intelligence in healthcare industry is rapidly expanding as providers seek cost-saving tools for diagnostics and administrative tasks. Regulatory scrutiny on AI medical devices remains high, requiring rigorous validation processes that can impact time-to-market and revenue recognition. Competition from large tech giants and established EHR vendors is intensifying, pressuring margins for specialized AI startups.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $3.9M | $5.9M | $594.8K |
| Cost of Revenue | $6.3M | $3.9M | $0 |
| Gross Profit | $-2.4M | $1.9M | $594.8K |
| Operating Expenses | $22.7M | $13.4M | $3.4M |
| Operating Income | $-25.2M | $-11.4M | $-2.8M |
| G&A | $15.9M | $9.3M | $2.6M |
| Marketing | — | — | $65.0K |
| Stock-Based Comp | $15.2M | $8.3M | $599.5K |
| D&A | $3.6M | $2.8M | $31.9K |
| Depreciation | — | — | $31.9K |
| Amortization | — | — | $30.8K |
| Other OpEx | $6.8M | $4.1M | $816.0K |
| Non-Operating Income | $-307.4K | $-83.0K | $-109.1K |
| Interest Expense | $276.9K | $83.0K | $52.2K |
| Pre-Tax Income | $-25.5M | $-11.5M | $-2.9M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-25.5M | $-11.5M | $-2.9M |
| Discontinued Ops | $50.9M | $0 | $-829.6K |
| Net Income | $25.5M | $-11.5M | $-3.8M |
| Minority Interest | $0 | $0 | $-172.1K |
| Net to Common | $25.5M | $-11.5M | $-3.6M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $265.2K | $2.6M | $418.8K |
| Cash & Equivalents | $258.0K | $57.8K | — |
| Prepaid Expenses | $7.2K | $249.2K | $11.0K |
| Other Current Assets | $0 | $2.3M | $407.8K |
| Long-Term Assets | $6.3M | $1.3M | $386.7K |
| PP&E (Net) | $5.3M | $1.3M | $42.1K |
| Intangibles | — | — | $51.4K |
| Operating Leases | — | — | $95.5K |
| Other LT Assets | $1.0M | $0 | $197.7K |
| Total Assets | $6.6M | $3.9M | $805.5K |
| Current Liabilities | $3.0M | $3.7M | $3.1M |
| Accounts Payable | $293.7K | $975.7K | $123.6K |
| Current Leases | — | — | $26.8K |
| Other Current Liab | $2.6M | $2.7M | $2.8M |
| Long-Term Liabilities | $4.1M | $4.1M | $85.0K |
| LT Operating Leases | — | — | $77.5K |
| Other LT Liab | — | — | $7.5K |
| Total Liabilities | $7.1M | $7.8M | $3.1M |
| Shareholders' Equity | $-509.9K | $-3.9M | $-2.3M |
| Paid-In Capital | $72.6M | $81.2M | $82.0M |
| Retained Earnings | $-73.1M | $-85.1M | $-88.7M |
| Total L&E | $6.6M | $3.9M | $805.5K |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $25.5M | $-11.5M | $-3.8M |
| Non-Cash Adjustments | $-29.1M | $6.4M | $2.9M |
| Working Capital Changes | $191.3K | $1.0M | $17.4K |
| Cash from Operations | $-3.4M | $-4.1M | $-848.5K |
| Capital Expenditures | $0 | $1.7K | $2.2K |
| Cash from Investing | $3.2M | $4.2M | $1.2M |
| Cash from Financing | $-50.0K | $-243.2K | $0 |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-232.3K | $-200.2K | $343.5K |
| Beginning Cash | $490.3K | $258.0K | $57.8K |
| Ending Cash | $258.0K | $57.8K | $401.3K |
Frequently Asked Questions
How does MedWellAI, Inc. make money?
The company derives revenue primarily from software licensing agreements and subscription-based SaaS models for its AI diagnostic engines. Additional streams include implementation services, ongoing maintenance contracts for hospital networks, and data analytics consulting for medical research institutions.
What are the main risks for MWAI?
Significant cash burn from operations coupled with a substantial retained earnings deficit of $88.7M raises concerns about long-term liquidity sustainability. The company's recent revenue collapse in 2025 suggests potential market contraction or loss of key enterprise clients. High non-operating losses and interest expenses indicate financial distress that could impact solvency without immediate capital injection.
What is MWAI's competitive advantage?
MedWellAI possesses a proprietary machine learning algorithm trained on diverse medical datasets that offers high predictive accuracy for early disease detection. The firm maintains low capital expenditure relative to revenue due to its software-centric business model which reduces infrastructure costs. Its agile OTC listing allows for rapid fundraising and strategic pivots compared to larger, more regulated peers.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.